Glucosamine/chondroitin/primorine combination therapy for osteoarthritis

Drugs of Today

Volumn 45, Issue 1, 2009, Pages 32-45

  Fox, Beth Anne ^a,c   Stephens, Mary M ^b  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

^b CHRISTIANA CARE HEALTH SYSTEM   (United States)

^c TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CELECOXIB; CHONDROITIN; CHONDROITIN SULFATE; DICLOFENAC; GLUCOSAMINE; GLUCOSAMINE SULFATE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PRIMORINE; REACTIVE OXYGEN METABOLITE; RELAMINE; RETINOL; THIOCTIC ACID; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL CRAMP; ALOPECIA; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISABILITY; DISEASE COURSE; DOSE RESPONSE; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HIP OSTEOARTHRITIS; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; KNEE OSTEOARTHRITIS; LIPID BLOOD LEVEL; MASTALGIA; NAUSEA; NECROTIZING ENTEROCOLITIS; NEOPLASM; NONHUMAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPONDYLOSIS; THROMBOPHLEBITIS; THYROID DISEASE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 63449101107     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Woolf, A.D., Pfleger, B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003, 81(9): 646-56.
2. Keenan, A.M., Tennant, A., Fear, J. et al. Impact of multiple joint problems on daily living tasks in people in the community over age fifty-five. Arthritis Rheum 2006, 55(5): 757-64.
3. Sprangers, M.A., de Regt, E.B., Andries, F. et al. Which chronic conditions are associated with better or poorer quality of life? J Gin Epidemiol 2000, 53(9): 895-907.
4. Hootman, J.M., Helmick, D.G. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum 2006, 54: 226-9.
5. Felson, D.T. Clinical practice: Osteoarthritis of the knee. N Engl J Med 2006, 354(8): 841-8.
6. Ricci, J.A, Stewart, W.F., Chee, E. et al. Pain exacerbation as a major source of lost productive time in US workers with arthritis. Arthritis Rheum 20 05, 53(5): 673-81.
7. Mapel, D.W., Shainline, M., Paez, K. et al. Hospital, pharmacy, and outpatient costs for osteoarthritis and chronic back pain. J Rheumatol 2004, 31(3): 573-83.
8. Institute of Medicine, National Research Council. Glucosamine: Prototype monograph summary. In: Dietary Supplements: A Framework for Evaluating Safety. The National Academies: Washington, D.C. 2005, 363-6.
9. Owens, S., Wagner, P., Vangsness, C.T. Jr. Recent advances in glucosamine and chondroitin supplementation. J Knee Surg 2004,17(4): 185-93.
10. de los Reyes, G.C., Koda, R.T., Lein, E.J. Glucosamine and chondroitin sulfates in the treatment of osteoarthritis: A survey. Prog Drug Res 2000, 55: 81-103.
11. Anderson, J.W., Nicolosi, R.J., Borzelleca, J.F. Glucosamine effects in humans: A review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol 2005, 43(2): 187-201.
12. Gorsline, R.T., Kaeding, C.C. The use ofNSAIDs and nutritional supplements in athletes with osteoarthritis: Prevalence, benefits, and consequences. Clin Sports Med 2005,24(1): 71-82.
13. Ronca, F., Palmieri, L, Panicucci, P., Ronca, G. Anti-inflammatory activity of chondroitin sulfate. Osteoarth Cartil 1998, 6(Suppl A): 14-21.
14. Gouze, J.N., Gouze, E., Popp, M.P. et al. Exogenous glucosamine globally protects chodrocytes from the arthritogenic effects of lL-1. Arthritis ResTher 2006, 8(6): R173.
15. Gouze, J.N., Bianchi, A., Becuwe, P. et al. Glucosamine modulates IL-Tinduced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-kappa B pathway. FEBS Lett 2002, 510(3): 166-70.
16. Largo, R., Alvarez-Soria, M.A., Diez-Ortega, I. et al. Glucosamine inhibits IL-l-beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarth Cartil 2003,11: 290-8.
17. Uitterlinden, E.J., Jahr, H., Koevoet, J.L. et al. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarth Cartil 2006,14: 250-7.
18. Bassleer, C, Henrotin, Y, Franchimont, P. In-vitro evaluation of drugs proposed as chondroprotective agents. Int J Tissue React 1992,14(5): 231-41.
19. Monfort, J., Nacher, M., Montell, E., Vila, J., Verges, J, Benito, P. Chondroitin sulfate and hyaluronic acid (500-730 kDa) inhibit stromelysin-lsynthesis in human osteoarthritic chondrocytes. Drugs Exp Clin Res 2005, 31(2): 71-6.
20. Jomphe, C, Gabriac, M., Hale, T.M. et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor kappaB in interleukein-lbeta- stimulated chondrocytes. Basic Clin Pharmacol Toxicol 2007, Nov 5 [Epub ahead of print].
21. Clegg, D.O., Reda, D.J., Harris, C.L. et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354(8): 795-808.
22. Herreri-Beaumont, G., Ivorra, J.A., Del Carmen Trabado, M. et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007, 56(2): 555-67.
23. McAlindon, T.E., LaValley, M.P., Gulin, J.P., Felson, D.T. Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA 2000, 283(11): 1469-75.
24. Richy, R, Bruyere, 0., Ethgen, 0. et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: A comprehensive meta-analysis. Arch intern Med 2003,163(13): 1514-22.
25. Bruyere, 0., Honore, A., Ethgen, 0. et al. Correlation between radiographic severity of knee osteoarthritis and future disease progression. Results from a 3-year prospective, placebo-controlled study evaluating the effect of glucosamine sulfate. Osteoarth Cartil 2003,11:1-5.
26. Poolsup, N., Suthisiang, C, Channark, P., Kittikulsuth, W. Glucosamine long-term treatment and the progression of knee osteoarthritis: Systematic review of randomized controlled trials. Ann Pharmacother 2005, 39(6): 1080-7.
27. Bruyere, 0., Pavelka, K., Rovati, L.C., et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: Results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarth Cartil 2007, Jul 26 [Epub ahead of print].
28. Michel, B.A., Stucki, G., Frey, D. gt al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee. Arthritis Rheum 2005, 52(3): 779-786.
29. Pham, T., Cornea, A., Blick, K.E. et al. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. Am J Med Sci 2007, 333(6): 333-39.
30. Monauni, T, Zenti, M.G., Cretti, A. et al. Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes 2000, 49(6): 926-35.
31. Hathcock, J.N., Shao, A. Risk assessment for glucosamine and chondroitin sulfate. Reg Toxicol Pharmacol 2007, 47 78-83.
32. Mazieres, B., Hucher, M., Zaim, M., Garnero, P. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: A multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2007, 66(5): 639-45.
33. Leeb, B., Schweitzer, H., Montag, K., Smolen, J. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000, 27(1): 205-11.
34. Tallia, A.F., Cardone, D.A. Asthma exacerbation associated with glucosamine-chondroitin supplement. J Am Board Fam Pract 2002,15(16): 481-4.
35. Shapiro, H.K. Carbonyl-trapping therapeutic strategies. Am J Ther 1998, 5(5): 323-53.
36. Yudoh, K., van Trieu, N., Nakamura, H. et al. Potential involvement of oxidative stress in cartilage senescence and development of osteoarthritis: Oxidative stress induces chondrocyte telomere instability and downregulation of chondrocyte function. Arthritis Res Ther 2005, 7 380-91.
37. Thomson Healthcare. PDR Health: Para-amino-benzoic acid. Available at: http://www.pdrhealth.com/drug-info/ nmdrugprofiles/nutsupdrugs/par-0194. shtml. Accessed September 25, 2007.
38. Thomson Healthcare. PDR Health: Alpha-lipoic acid. Available at: http://www.pdrhealth.com/drug-info/ nmdrugprofiles/nutsupdrugs/alp-0159.shtml. Accessed September 25, 2007.
39. Pershadsingh, H. Alpha-lipoic acid: Physiologic mechanisms and indication for the treatment of metabolic syndrome. Expert Opin Investig Drugs 2007, 16(3): 291-302.
40. Thomson Healthcare: PDR Health: Vitamin E. Available at: http://www.pdrhealth.com/drugjnfo/nmdrugprofiles/nut supdrugs/vitJ3266. Accessed October 16, 2007.
41. Mustacich, D., Bruno, R., Traber, M. Vitamin E. Vitam Horm 2007, 76:1-21.
42. Suzuki, D., Miyata, T., Kurokawa, K. Carbonyl stress. Contrib Nephrol 2001,134: 36-45.
43. Takeuchi, Y, Miyamoto, T, Kakizawa, T, Shigematsu, S., Hashizume, K. Insulin autoimmune syndrome possibly caused by alpha lipoic acid. Intern Med 2007, 46(5): 237-9.
44. Furukawa, N., Miyamura, N., Nishida, K. et al. Possible relevance of alpha lipoic acid contained in a health supplement in a case of autoimmune syndrome. Diabetes Res Clin Pract 2007, 75(3): 366-7.
45. ATBC Study Group. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation. JAMA 2003, 290: 476-85.
46. Canter, P.H., Wider, B., Ernst, E. The antioxidant vitamins A, C, E, and selenium in the treatment of arthritis: A systematic review of randomized clinical trials. Rheumatol 2007, 46: 1223-33.
47. Machtey, I., Ouaknine, L. Tocopherol in osteoarthritis: A controlled pilot study. J Am Geriatr Soc 1978, 26(7): 328-30.
48. Blankenhorn, G. Clinical effectiveness of Spondyvit (vitamin E) in activated arthroses. A multicenter placebo-controlled double-blind study. Z Orthop 1986,124(3): 340-3.
49. Brand, C., Snaddon, J., Bailey, M., Cicuttini, F. Vitamin E is ineffective for symptomatic relief of knee osteoarthritis: A six month double blind randomised placebo controlled study. Ann Rheum Dis 2001, 60(10): 946-9.
50. Wluka, A.E., Stuckey, S., Brand, C., Cicuttini, F.M. Supplementary vitamin E does not affect the loss of cartilage volume in knee osteoarthritis: A 2 year double blind randomized placebo controlled study. J Rheumatol 2002, 29: 585-591.
51. Scherak, 0., Kolarz, C, Schodl, C, Blankenhorn, G. High dosage vitamin E therapy in patients with activated arthrosis. Z Rheumatol 1990,49(6): 369-73.
52. Link, P., Dreher, R. D-α-Tocopherolacetat versus diclofenac in der therapie der aktivierten arthrose. Der Kassenarzt 1990, 22: 48-52.